HelpLine 1-800-298-2436

FDA Approves New Drug Combination for NSCLC Patients With BRAF V600E Mutation

Thursday, June 22, 2017 - The U.S. Food and Drug Administration (FDA) granted regular approval for a new drug combination of Tafinlar (dabrafenib) and Mekinist (trametinib) for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation. Both Tafinlar and Mekinist are targeted therapies and taken orally. Niether drug is approved alone for patient's with NSCLC, only in combination. These are the first FDA approvals specifically for treatment of patients with BRAF V600E mutation-positive metastatic NSCLC. 

Click here to learn more.